Tepotinib
Drug Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Tepotinib |
| Trade Name | Tepmetko |
| Synonyms | EMD1214063|EMD-1214063|EMD 1214063|MSC2156119|MSC-2156119|MSC2156119J |
| Drug Descriptions |
Tepmetko (tepotinib) selectively binds to the proto-oncogene hepatocyte growth factor receptor (HGFR or c-Met), which inhibits c-Met phosphorylation and disrupts c-Met-mediated signaling pathways, thereby suppressing tumor growth in tumor cells with activated or overexpression of c-Met protein (PMID: 32328660). Tepmetko (tepotinib) is FDA approved for use in patients with metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations (FDA.gov). |
| DrugClasses | MET Inhibitor 59 |
| CAS Registry Number | 1100598-32-0 |
| NCIT ID | C88314 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Amivantamab-vmjw + Tepotinib | Amivantamab-vmjw Tepotinib | 0 | 1 |
| Cetuximab + Tepotinib | Cetuximab Tepotinib | 0 | 1 |
| Dacomitinib + Tepotinib | Dacomitinib Tepotinib | 0 | 0 |
| Entrectinib + Tepotinib | Entrectinib Tepotinib | 0 | 0 |
| Erlotinib + Tepotinib | Erlotinib Tepotinib | 0 | 0 |
| Gefitinib + Tepotinib | Gefitinib Tepotinib | 0 | 0 |
| Infigratinib + Tepotinib | Infigratinib Tepotinib | 0 | 0 |
| Osimertinib + Tepotinib | Osimertinib Tepotinib | 0 | 2 |
| Pembrolizumab + Tepotinib | Pembrolizumab Tepotinib | 0 | 1 |
| Poziotinib + Tepotinib | Poziotinib Tepotinib | 0 | 0 |
| Radiotherapy + Tepotinib | Radiotherapy Tepotinib | 0 | 0 |
| Ramucirumab + Tepotinib | Ramucirumab Tepotinib | 0 | 1 |
| Sotorasib + Tepotinib | Sotorasib Tepotinib | 0 | 0 |
| Tepotinib | Tepotinib | 0 | 9 |
CKB BOOST